New vaccine trains immune system to fight ovarian cancer
NCT ID NCT05773859
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized vaccine made from a patient's own immune cells and tumor material in 10 women with advanced ovarian cancer. The goal is to see if the vaccine can safely boost the immune system to recognize and attack cancer cells after chemotherapy. The study focuses on immune response and safety, not yet on curing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dendritic cell vaccine made from the patient's own immune cells and tumor material
What this could lead to
If it works, this could point toward a new way to train the immune system to attack ovarian cancer cells, potentially improving long-term control of the disease.
What could go wrong
This is an early phase 1/2 trial with only 10 participants, so results are very preliminary. The vaccine may not produce a strong immune response or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radboud University Medical Center
RECRUITINGNijmegen, Gelderland, 6500 HB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact